| Bioactivity | FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good oral bioavailability[1]. |
| Target | Ki: 0.17 nM (FXIa) |
| In Vivo | FXIa-IN-10 (Compound 3f) (1.7+2.0 and 8.5+10.0 (bolus + infusion) mg/kg; i.v.; twice) shows antithrombotic efficacy in a rabbit AV shunt thrombosis model[1].FXIa-IN-10 (0-10 mg/kg; p.o.; once) demonstrates oral bioavailability in preclinical species (rat 36.4%, dog 80.5%, and monkey 43.0%)[1]. Animal Model: |
| Name | FXIa-IN-10 |
| CAS | 2816108-08-2 |
| Formula | C23H18Cl2F3N9O2 |
| Molar Mass | 580.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xu G, et al. Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions. J Med Chem. 2022 Aug 11;65(15):10419-10440. |
FXIa-IN-10
CAS: 2816108-08-2 F: C23H18Cl2F3N9O2 W: 580.35
FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good ora
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.